ArticleArchiv der Pharmazie2026
4-(5'-Dimethylamino)-Naphthalenesulfonyl-2(3H)-Benzoxazolone (W3D) Ameliorated COPD Lung Injury Through Regulating Macrophage Polarization Mediated by Glycolysis.
Article in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) remains a significant global health challenge, which urges the discovery of novel drugs. In this article, we investigated the therapeutic potential and action mechanism of a new benzoxazolone derivative, 4-(5'-dimethylamino)-naphthalenesulfonyl-2(3H)-benzoxazolone (W3D), synthesized by our research team, against COPD both in vivo and in vitro. The results demonstrated that W3D could down-regulate inflammatory cytokines such as interleukin-6 (IL-6), interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and MMP-9, thereby reducing airway inflammation and improving lung function, which together alleviated lung injury in COPD. Meanwhile, W3D increased the expression of tight junction proteins claudin-1 and occludin and attenuated the activation of the Toll-like receptor 4/nuclear factor kappa B (TLR4)/NF-κB) signaling pathway to maintain the integrity of bronchial epithelial cells. Additionally, W3D restored the expression of glycolytic enzymes such as LDHA, PKM2, and HK2 to modulate lactate levels, thereby correcting glycolytic pathway dysregulation. W3D decreased intracellular lactate content, down-regulated global Kla levels and H3K18la expression, and regulated macrophage polarization in cigarette smoke extract (CSE)-induced macrophages. Furthermore, these therapeutic effects of W3D were compromised in the presence of the glycolytic inhibitor 2-deoxy-d-glucose (2-DG), indicating that W3D regulated macrophage polarization by inhibiting glycolysis. Our results demonstrated that glycolysis was activated in macrophages exposed to CSE and served as a key role in the macrophage polarization process. Inhibiting glycolysis in macrophages might be a potential therapeutic direction for COPD. In addition, given the confirmed protective effect against COPD, W3D could serve as a promising lead compound for further structural modifications of innovative drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.